Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jolijn J Kragt

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2011
Clinical scales in progressive MS: predicting long-term disabilityLibertje V A E Bosma, Jolijn J Kragt, Dirk L Knol, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2010
Outcome measurement in multiple sclerosis: detection of clinically relevant improvementLisa M L van Winsen, Jolijn J Kragt, Erwin L J Hoogervorst, et al.
BMC Neurology|March 26, 2009
The size of the treatment effect: do patients and proxies agree?Femke A H van der Linden, Jolijn J Kragt, Jeremy C Hobart, et al.
BMC Neurology|March 1, 2008
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two yearsFemke A H van der Linden, Jolijn J Kragt, Margarethe van Bon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2011
Clinical scales in progressive MS: predicting long-term disabilityLibertje V A E Bosma, Jolijn J Kragt, Dirk L Knol, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2010
Outcome measurement in multiple sclerosis: detection of clinically relevant improvementLisa M L van Winsen, Jolijn J Kragt, Erwin L J Hoogervorst, et al.
BMC Neurology|March 26, 2009
The size of the treatment effect: do patients and proxies agree?Femke A H van der Linden, Jolijn J Kragt, Jeremy C Hobart, et al.
BMC Neurology|March 1, 2008
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two yearsFemke A H van der Linden, Jolijn J Kragt, Margarethe van Bon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Pageof 1